Claims show BMS's Abilify remains strong

Generics are no match for Bristol-Myers Squibb's antipsychotic Abilify (aripiprazole) among patients with bipolar disorder. Research firm Decision Resources found that the branded drug's “favorable perceived tolerability profile and its regulatory approval for the multiple stages of the illness drive its use.”

The researchers noted that a review of patient-level claims data showed the medication captured “the second-highest patient share among atypical psychotics” prescribed for the disorder. They also noted that the drug's market share has remained stable for five years, despite competition from AstraZeneca's Seroquel (quetiapine) which has gone generic, among others.